Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

NCT00960752 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: gp100
DRUG: R848 gel
DRUG: MAGE-3

Sponsor

M.D. Anderson Cancer Center